GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK shares nudged higher in early trading Tuesday, hovering close to a one-year peak ahead of the British drugmaker’s earnings report. The stock gained 0.1% to 1,926.5 pence, after touching 1,928.5 pence earlier.

3 February 2026

Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Shares of Wave Life Sciences Ltd dropped 6.7% on Friday, ending the day at $13.84. The stock swung between a high of $15.09 and a low of $13.76 during the session.

11 January 2026

Biotechnology·NASDAQ:WVE·Stock Market

Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now

Wave Life Sciences Ltd shares fell about 5.6% on Friday, down 83 cents at $14.00, after trading between $13.99 and $15.09. The drop came even as biotech exchange-traded funds rose, with the SPDR S&P Biotech ETF up about 1% and the iShares Nasdaq Biotechnology ETF up about 0.5%.

9 January 2026

NASDAQ:WVE·Stock Market

Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

Wave Life Sciences shares rose 4.4% to $15.82 in midday trade on Wednesday. The stock has stayed in motion as investors circle back to obesity plays tied to a gene target called INHBE.

7 January 2026

Biotechnology·NASDAQ:ARWR·NASDAQ:WVE·Stock Market

Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences Ltd shares jumped about 17% on Tuesday, extending sharp swings in the obesity drug trade as investors sized up the next set of clinical readouts.

6 January 2026

Biotechnology·NASDAQ:WVE·Stock Market

Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

Wave Life Sciences Ltd shares fell $1.34, or 8.4%, to $14.61 in afternoon trade on Monday, extending a sharp pullback in the clinical-stage biotech even as the company flagged an investor-conference appearance next week.

5 January 2026

NASDAQ:WVE·Stock Market

Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

Wave Life Sciences shares closed down 6.2% on Friday at $15.95, with the Nasdaq-listed biotech swinging between $15.53 and $17.23 in the session.

4 January 2026

NASDAQ:WVE·Stock Market

Wave Life Sciences stock drops 6% as WVE traders size up next obesity data

Wave Life Sciences Ltd shares closed down 6.2% on Friday at $15.95, ending the first full U.S. trading session of 2026 with a sharp pullback.

4 January 2026

Biotechnology·NASDAQ:WVE·Stock Market

Wave Life Sciences stock tumbles 8.5% in first 2026 session as traders refocus on next WVE-007 readout

Wave Life Sciences Ltd shares slid on Friday, giving back part of last month’s obesity-driven run as the biotech sector wobbled in the first U.S. session of 2026. The stock was down about 8.5% at $15.55 as of 2:13 p.m. ET.

2 January 2026

Biotechnology·NASDAQ:WVE·Stock Market

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

New York, Dec. 26, 2025 — Wave Life Sciences Ltd. is trading at $18.12, down about 0.74% in the late morning session. The move comes while biotech is broadly softer—SPDR S&P Biotech ETF is down about 1.07% and iShares Nasdaq Biotechnology ETF is down about 0.63%—even as the broader market edges higher, with SPY and QQQ both modestly in the green.

26 December 2025

NASDAQ:WVE·Pharmaceutical Industry·Stock Market

Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences Ltd. is ending 2025 as one of biotech’s most watched “story stocks”—the kind that can go from sleepy to screaming in a single premarket headline, then spend weeks digesting what just happened.

24 December 2025

Biotechnology·NASDAQ:WVE·Stock Market

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences Ltd. is back in the spotlight on December 18, 2025—not because of a brand-new press release, but because the stock is still digesting one of the most volatile biotech weeks of the year.

18 December 2025

NASDAQ:WVE

Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility

December 16, 2025 — Wave Life Sciences Ltd. is back in the spotlight after a roller-coaster week that mashed together three classic biotech ingredients: eye-popping early clinical data, a rapidly upsized stock offering, and a stack of Wall Street price-target hikes.

16 December 2025

Biotechnology·NASDAQ:WVE·Stock Market

US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns

U.S. stocks closed mixed on Thursday, December 11, 2025, as a historic surge in the Dow clashed with a sharp tech sell‑off led by Oracle and a wave of brutal collapses in thinly traded micro‑caps.

11 December 2025

NASDAQ:ORCL·NASDAQ:RZLT·NASDAQ:WVE·Stock Market·US Economy

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences Ltd., a clinical‑stage biotechnology company focused on RNA‑based medicines, has gone from relative obscurity to market headline in a matter of days.

11 December 2025

Biotechnology·NASDAQ:WVE·Pharmaceutical Industry·Stock Market

Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More

As Wall Street wakes up on Tuesday, December 9, 2025, investors are still digesting a wild Monday session in which a handful of biotech and tech names exploded higher, even as the major indices finished in the red ahead of tomorrow's pivotal Federal Reserve decision.Reuters+ 1

9 December 2025

NASDAQ:CFLT·NASDAQ:GP·NASDAQ:WVE·Stock Market·US Stocks

Most Active Stocks Today (December 9, 2025): Nvidia, Tesla, Wave Life Sciences and Confluent Lead a Fed-Focused Wall Street

US investors are crowding into a tight cluster of high-conviction themes today: artificial intelligence chips, blockbuster media and software deals, obesity drugs, and speculative AI small caps.

9 December 2025

NASDAQ:CFLT·NASDAQ:NVDA·NASDAQ:TSLA·NASDAQ:WVE·Stock Market

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences Ltd. has suddenly gone from sleepy small‑cap biotech to front‑page obesity contender. After unveiling striking Phase 1 data for its RNA obesity drug WVE‑007 on December 8, 2025, the stock rocketed roughly 147% to about $18.52 per share, pushing the company’s market cap to around $3.0 billion as of early December 9. MLQ

9 December 2025

Biotechnology·NASDAQ:WVE·Pharmaceutical Industry·Stock Market

Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences Ltd. just delivered one of the wildest biotech moves of 2025. On Monday, December 8, 2025, the stock rocketed after the company reported positive Phase 1 obesity drug data for WVE‑007 and simultaneously launched a $250 million equity offering.

9 December 2025

NASDAQ:WVE·Pharmaceutical News·Stock Market

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Wave Life Sciences Ltd. staged a spectacular rally on Monday after unveiling positive interim data from its Phase 1 INLIGHT trial for obesity drug candidate WVE‑007. Shares surged from a close of $7.49 on Friday, December 5 to intraday levels around $17–18, a gain in the range of 120%–140% and a new multi‑year high. Yahoo Finance+2Investing.com+2

8 December 2025

Biotechnology·NASDAQ:WVE

1 2 Next

Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now

Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

Wave Life Sciences stock drops 6% as WVE traders size up next obesity data

Wave Life Sciences stock tumbles 8.5% in first 2026 session as traders refocus on next WVE-007 readout

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility

US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More

Most Active Stocks Today (December 9, 2025): Nvidia, Tesla, Wave Life Sciences and Confluent Lead a Fed-Focused Wall Street

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

TechStock² Updates

Brent Climbs 2% to $89.70 as Iran Negotiations Break Down, Oil Prices Surge

Australia Stock Market Today 28/08/2026 [UPDATE: 12:40 AEST] [WAM Dividend Cut Deepens Selloff as ASX Rebound Fades]

U.S. Home Buyers Gain Bargaining Power as Mortgage Rate Climbs to 6.66%, Slowing Demand

PagerDuty Shares Dip 0.2% Post-Market; 15% Workforce Reduction Boosts Profit Guidance

Elastic shares surge nearly 20% post-market as revenue reaches $478 million

US Stock Market Today Updates

Asia Stock Market Today Updates

UK Stock Market Today Updates

Australia Stock Market Today Updates

Top Stock Picks

NVIDIA

Meta Platforms

Alphabet

Amazon

Microsoft

Investment Disclaimer